［1］LIU WH，DENG HQ，WU ZQ.Effects of different TNM stages on the prognosis of patients with radical cystectomy for bladder cancer［J］.Modern Oncology，2016，24(20)：3240-3243.［刘卫华，邓红琴，吴振启.膀胱癌不同TNM分期对根治性膀胱切除术患者预后的影响［J］.现代肿瘤医学，2016，24(20)：3240-3243.］
［2］Antoni S，Ferlay J，Soerjomataram I，et al.Bladder cancer incidence and mortality：A global overview and recent trends［J］.European Urology，2017，71(1)：96-108.
［3］Witjes JA.Re：Trends in the use of perioperative chemotherapy for localized and locally advanced muscle-invasive bladder cancer：a sign of changing tides［J］.European Urology，2016，195(6)：1721.
［4］ZHENG YP，ZHANG GY，LIU YX，et al.Effect analysis of bladder perfusion chemotherapy combined with intravenous chemotherapy after transurethral cystectomy for the treatment of high-grade T1 bladder cancer［J］.Chinese Journal of Urology，2017，38(8)：578-580.［郑宇朋，张光银，刘跃新，等.经尿道膀胱肿瘤切除术后膀胱灌注化疗联合静脉化疗治疗高级别T1期膀胱癌的疗效分析［J］.中华泌尿外科杂志，2017，38(8)：578-580.］
［5］HU XP，XUE WR，WANG W，et al.Clinicopathological features of incidental prostate cancer in patients with radical bladder cancer and its effect on prognosis［J］.Chinese Journal of Urology，2016，37(5)：340-343.［胡小鹏，薛文瑞，王伟，等.膀胱癌根治术患者前列腺偶发癌的临床病理特点及其对预后的影响［J］.中华泌尿外科杂志，2016，37(5)：340-343.］
［6］Chou R，Selph S，Buckley DI，et al.Intravesical therapy for the treatment of non-muscle-invasive bladder cancer：A systematic review and Meta-analysis［J］.Journal of Urology，2017，197(5)：1189-1199.
［7］LI WY，LI QW，WANG S，et al.Laparoscopic radical cystectomy+ileal neobladder in situ for the treatment of invasive bladder cancer［J］.Modern Oncology，2017，25(21)：3448-3451.［李文永，李庆文，汪盛，等.腹腔镜根治性膀胱切除+原位回肠新膀胱术治疗浸润性膀胱癌的临床疗效分析［J］.现代肿瘤医学，2017，25(21)：3448-3451.］
［8］Rapisarda V，Caltabiano R，Musumeci G，et al.Analysis of fibulin-3 after exposure to asbestos-like fibers［J］.Environmental Research，2017，156(10)：381-387.
［9］Palou J，Pisano F，Sylvester R，et al.Recurrence，progression and cancer-specific mortality according to stage at re-TUR in T1G3 bladder cancer patients treated with BCG：Not as bad as previously thought［J］.World Journal of Urology，2018，16(3)：1-7.
［10］WANG Y，XING QF，LIU XQ，et al.Relationship between metabolic syndrome and its metabolic components and prognosis of T1-stage high-grade bladder cancer［J］.Chinese Journal of Urology，2016，37(7)：498-502.［王一，邢庆菲，刘晓强，等.代谢综合征及其代谢组分与T1期高级别膀胱癌的预后关系［J］.中华泌尿外科杂志，2016，37(7)：498-502.］
［11］Nandhu MS，Kwiatkowska A，Bhaskaran V，et al.Tumor-derived fibulin-3 activates pro-invasive NF-κB signaling in glioblastoma cells and their microenvironment［J］.Oncogene，2017，36(34)：4875-4886.
［12］Li Y，Hu Y，Liu C，et al.Human fibulin-3 protein variant expresses anti-cancer effects in the malignant glioma extracellular compartment in intracranial xenograft models［J］.Oncotarget，2017，8(63)：106311-106323.
［13］ZHU L，XU L，MOU CL，et al.Relationship between fibulin-3 level and clinical pathology in patients with colon cancer［J］.Advances in Modern General Surgery in China，2017，18(10)：767-769.［朱磊，徐亮，牟春露，等.结肠癌患者Fibulin-3水平与临床病理关系［J］.中国现代普通外科进展，2017，18(10)：767-769.］
［14］GU L.Preliminary study on the expression and function of fibulin-3 in breast cancer［D］.Nanchang:Nanchang University，2018.［辜雷.Fibulin-3在乳腺癌中的表达及功能的初步研究［D］.南昌:南昌大学，2018.］
［15］Caltabiano R，Loreto C，Vitale E，et al.Fibulin-3 immunoexpression in malignant mesothelioma due to fluoro-edenite：A preliminary report［J］.Future Oncology，2018，14(6)：53-57.
［16］Battolla E，Canessa PA，Ferro P，et al.Comparison of the diagnostic performance of Fibulin-3 and mesothelin in patients with pleural effusions from malignant mesothelioma［J］.Anticancer Research，2017，37(3)：1387-1391.
［17］Lin Z，Zhuo W，Guobiao LI，et al.Fibulin-3 may improve vascular health through inhibition of MMP-2/9 and oxidative stress in spontaneously hypertensive rats［J］.Molecular Medicine Reports，2016，13(5)：3805-3812.
［18］Han AL，Veeneman BA，El-Sawy L，et al.Fibulin-3 promotes muscle-invasive bladder cancer［J］.Oncogene，2017，36(37)：5243-5251.
［19］Hu B，Nandhu MS，Sim H，et al.Fibulin-3 promotes glioma growth and resistance through a novel paracrine regulation of Notch signaling［J］.Cancer Research，2012，72(15)：3873-3885.